Clinical Guidance for STIs

July 18, 2025

Bicillin L-A®

On July 10, 2025, King Pharmaceuticals, a subsidiary of Pfizer, of specific referenced lots of Bicillin® L-A (Penicillin G Benzathine Injectable Suspension). Further details and priority actions for health departments and healthcare providers are available from the Dear Colleague Letter.

On 1/16/2024, the FDA announced that they have (benzathine benzylpenicillin injection, powder, for suspension). See more in this CDC letter. See more in this CDC letter. , (Benzathine Benzylpenicillin Tetrahydrate) Powder and diluent for suspension for injection, has also been allowed since July of 2024.

Bicillin L-A® is the first-line recommended treatment for syphilis and the only recommended treatment option for some patients.

CDC continues to monitor the situation and will post updates as needed.

CDC has produced guidance and resources for screening and treating STIs.

STI Treatment Guidelines

Healthcare provider using mobile device to browse treatment guidelines — 2021 STI Treatment Guidelines

2021 STI Treatment Guidelines provide CDC’s most current evidence-based recommendations for preventing, diagnosing and treating people who have, or are at risk for, STIs. Includes regimens, evidence tables, wall chart, and pocket guide.